The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
GottliebJ.A., BakerL.H., O'BryanR.M.Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother.1975; 6(2): 271–282.
2.
BramwellV., RoueseeJ., StewardW.Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization For Research And Treatment Of Cancer Soft Tissue And Bone Sarcoma Group. J Clin Oncol.1994; 12(6): 1137–1149.
3.
CreaganE.T., HahnR.G., AhmannD.L., EdmonsonJ.H., BiselH.F., EaganR.T.A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vin-cristine, and a single agent, methyl-CCNU, in advanced sarcomas. Cancer Treat Rep.1976; 60(9): 1385–1387.
4.
YapB.S., BakerL.H., SinkovicsJ.G.Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep.1980; 64(1): 93–98.
5.
BuiN.B., ChauvergneJ., HockeC., DurandM., BrunetR., CoindreJ.M.Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adri-amycin-dacarbazine (CYVADIC) Combination. Cancer Chemother Pharmacol.1985; 15(1): 82–85.
6.
PinedoH.M., BramwellV.H., MouridsenH.T.Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Cancer.1984; 53(9): 1825–1832.
7.
SantoroA., TurszT., MouridsenH.Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol.1995; 13(7): 1537–1545.
8.
PinedoH.M., VendrikC.P., StaquetM., KenisY., SylvesterR.E.O.R.T.C. protocol for the therapy of metastatic soft tissue sarcoma, a randomized trial. Eur J Cancer.1977; 13(7): 765–771.
9.
HemplingR.E., PiverM.S., BakerT.R.Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial. Am J Clin Oncol.1995; 18(4): 282–286.
10.
PatelS.R., WinchesterD.J., BenjaminR.S.A 15-year experience with chemotherapy of patients with paragan-glioma. Cancer.1995; 76: 1476–1480.
11.
PiverM.S., LeleS.B., MarchettiD.L., EmrichL.J.Effect of adjuvant chemotherapy on time to recurrence and survival of stage 1 uterine sarcomas. J Surg Oncol.1988; 38(4): 233–239.
12.
WallN., StarkhammarH.Chemotherapy of soft tissue sarcoma: a clinical evaluation of treatment over ten years. Acta Oncologica.2003; 42(1): 55–61.
13.
WilburJ.R., SutowW.W., SullivanM.P., GottliebJ.A.Chemotherapy of sarcomas. Cancer.1975; 36(2): 765–769.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–745.
17.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
KrisM.G., HeskethP.J., SomerfieldM.R.American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
BeckT.M.The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs.1995; 6(2): 237–239.
22.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
23.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
24.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
25.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anti-cancer Drugs.1998; 9(5): 381–385.
26.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emestogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
27.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
28.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
29.
StillwellT.J., BensonR.C.Jr.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
